VAERS Explorer
Back to explore

Report #2861637

Received Sep 26, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
NY
Recovered
Not recovered
Vaccinated
Sep 9, 2025
Onset
Sep 9, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALSUNK4ZS72IM

Symptoms (4)

ErythemaFeeling hotHypersensitivitySwelling

Symptom narrative

swelling, redness, warmth; redness; warmth; Likely allergic reaction; This non-serious case was reported by a other health professional and described the occurrence of swelling in a 68-year-old female patient who received Herpes zoster (Shingrix) (batch number 4ZS72, expiry date 26-APR-2027) for prophylaxis. On 09-SEP-2025, the patient received Shingrix (intramuscular) .5 ml. On 09-SEP-2025, less than a day after receiving Shingrix, the patient experienced swelling (Verbatim: swelling, redness, warmth), erythema (Verbatim: redness), feeling of warmth (Verbatim: warmth) and allergic reaction (Verbatim: Likely allergic reaction). The outcome of the swelling, erythema, feeling of warmth and allergic reaction were not resolved. It was unknown if the reporter considered the swelling, erythema, feeling of warmth and allergic reaction to be related to Shingrix. It was unknown if the company considered the swelling, erythema, feeling of warmth and allergic reaction to be related to Shingrix.